Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-632. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 7/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-632 SCHEMBL5705524 | 0.99 | KDR (0.98) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL438781 | 0.99 | KDR (0.98) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705560 | 0.97 | KDR (0.94) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705534 | 0.97 | KDR (0.94) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL5705655 | 0.95 | KDR (0.90) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3083706 | 0.93 | KDR (0.88) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3085641 | 0.93 | KDR (0.87) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3084090 | 0.93 | KDR (0.87) | KDRPDGFRBFLT1PLK4AURKA | |
| Osi-632 SCHEMBL6380035 | 0.93 | KDR (0.86) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL1786207 | 0.93 | KDR (0.86) | KDRPDGFRBFLT1PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4653019-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-11-26 | — | — | EP | claimed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | claimed |
| WO-2024246865-A1 | TRANSPLANT IMMUNOSUPPRESSION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024153229-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR TREATING BREAST CANCER | 江苏恒瑞医药股份有限公司 | 2024-07-25 | — | — | WO | claimed |
| WO-2023240271-A1 | USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY | FOUNTAIN THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | claimed |
| CN-115192564-B | Phenylalanine derivative, pharmaceutical composition and application thereof in tumor treatment | 四川大学华西医院 | 2023-11-17 | — | — | CN | claimed |
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| EP-1084114-B1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2004017964-A1 | COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES | PFIZER PRODUCTS INC. (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1337521-A1 | SALTS OF AN ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-20020151573-A1 | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002044158-A1 | SALTS OF A ISOTHIAZOLE-4-CARBOXAMIDE AND THEIR USE AS ANTI-HYPERPROLIFERATION AGENTS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | claimed |
| US-6235764-B1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2001-05-22 | — | — | US | claimed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | DNER, EGFR, NOTCH2 | KDR 498/4885PDGFRB 1586/4885FLT1 477/4885 |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | KDR 2745/4885PDGFRB 3361/4885FLT1 1112/4885 |
| US-20020151573-A1 | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | CPS1, FH, CS | KDR 2187/4885PDGFRB 2017/4885FLT1 930/4885 |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | KDR 2745/4885PDGFRB 3361/4885FLT1 1112/4885 |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | PRMT5, PRMT1, PRMT3 | KDR 45/4885PDGFRB 1358/4885FLT1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.